Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com


AstraZeneca Signs Development and Commercialization Agreement with Kyowa Hakko Kirin

Shots: Kyowa Kirin to receives upfront, regulatory & commercial milestones. AstraZeneca to get global rights to develop & commercialize Fasenra (beralizumab) for all indication across 14 Asian countries including Japan In Mar,2017 AstraZeneca & Kyowa Kirin collaborated to develop & commercialize Fasenra (beralizumab) for severe asthma and chronic obstructive pulmonary disease (COPD) in Asia Fasenra […]Read More

Weekly Snapshot

PharmaShots Weekly Snapshot (March 18-22, 2019)

Novartis Announces Spin-Off of Alcon Eye Care Business on April 9, 2019 Published: March 22, 2019 | Tags: Novartis, Announces, Spin-Off, Alcon, Eye Care, Business, April 9, 2019 Celgene Collaborates with Exscientia for its AI Drug Discovery Platform Published: March 22, 2019 | Tags: Celgene, Collaborates, Exscientia, AI, Drug Discovery Platform Biogen and Eisai Terminate P-III ENGAGE and […]Read More


Eisai Signs a Research Agreement with Cerveau Technologies for its

Shots: Eisai & Cerveau Technologies enter into a research collaboration to utilize Cerveau’s [F-18]MK-6240 in PET scan for assessing the status of neurofibrillary tangles (NFTs) in the brain The focus of the collaboration is to utilize Cerveau’s [F-18]MK-6240 as a biomarker and to evaluates its effect in Eisai’s neurodegenerative research studies Cerveau’s MK-6240 is a […]Read More

Biotech Pharma

Takeda Collaborates with LegoChem Biosciences (LCB) to Develop Antibody-Drug Conjugates

Shots: LCB to receive $7.25M upfront, $404M as regulatory & commercial milestones and royalties on sales of ADCs product. Takeda licenses rights for LCB’s ConjuAll technology including linker and conjugation platform to develop & commercialize targetted immune-oncology therapies for three targets The focus of the collaboration is to utilize LCB’s ADC technology including linker and […]Read More


Jazz Pharmaceuticals’ Sunosi (solriamfetol) Receives FDA’s Approval for the Treatment

Shots: The approval is based on P-III TONES study assessing Sunosi (solriamfetol) vs PBO in 900 patients with excessive daytime sleepiness associated with narcolepsy or Obstructive Sleep Apnea (OSA) The P-III TONES study results: @12wks. improvement in PGIc scale (68-74% receiving 75mg & 78-90% receiving 150mg); improvement in wakefulness (assessed in the maintenance of wakefulness […]Read More


Merck KGaA and Pfizer Terminates P-III JAVELIN Ovarian PARP 100

Shots: The termination is based on P-III JAVELIN Ovarian PARP 100 study (B9991030) results assessing Bavencio (avelumab) + CT followed by avelumab + Talzenna (talazoparib) vs PBO in 9,000 patients with locally advanced or metastatic ovarian cancer The termination is due to its third failure with unmet degree of benefit observed with avelumab in ovarian […]Read More